Pre­ci­sion medicine startup part­ners with Korean firm

BioSpectrum (Asia) - - Start-Up-News -

Wauwatosa-based pre­ci­sion medicine com­pany RPRD Di­ag­nos­tics LLC has formed a strate­gic part­ner­ship with South Korean biotech­nol­ogy firm Ori­ent Bio Inc. on a trade mis­sion to Korea. RPRD stands for Right Pa­tient Right Drug, and the com­pany fo­cuses on help­ing doc­tors find the safest drug for a pa­tient and re­duce neg­a­tive drug re­ac­tions. Ori­ent Bio, founded in 1959, pro­duces and sup­plies cat­a­log prod­ucts for the biotech­nol­ogy in­dus­try, in­clud­ing an­i­mal mod­els, lab­o­ra­tory sup­plies and med­i­cal equip­ment. It also pro­vides pre-clin­i­cal ser­vices for drug devel­op­ment, in­clud­ing ge­netic test­ing. The com­pa­nies signed a me­moran­dum of un­der­stand­ing in Seoul to ex­pand RPRD’s phar­ma­co­ge­net­ics test­ing ser­vices into new mar­kets, and for Ori­ent Bio to di­ver­sify into pre­ci­sion medicine and clin­i­cal phar­ma­co­ge­net­ics. RPRD re­cently launched CNT Panel, which is highly rel­e­vant for pa­tients of East Asian eth­nic­ity who may re­ceive thiop­urine drug treat­ment, pre­scribed for pa­tients with leukemia in ad­di­tion to other dis­eases.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.